随机尿白蛋白/肌酐与血清胱抑素C在诊断糖尿病肾病中的价值被引量：18

Significance of the ratio of casual urine albumin to creatinine and serum Cystatin C in diagnosis of diabetic nephropathy

下载PDF

导出

摘要目的评价随机尿白蛋白/肌酐比值(ACR)与血清胱抑素C(CysC)在诊断糖尿病肾病(DN)中的价值。方法选取临床确诊的DN患者29例,未明确诊断为DN的糖尿病患者111例,正常对照组27例,使用免疫透射比浊法和酶法测定患者的随机ACR与血清CysC水平。结果 DN患者组中随机ACR与血清CysC水平均高于糖尿病未明确诊断DN组(P<0.01),DN组中ACR与血清CysC水平呈正相关(P<0.01)。结论随机ACR与血清CysC可以作为监测DN发生的指标。 Objective To investigate the effects of the ratio of casual urine albumin to creatinine（ACR） and serum Cystatin C（CysC） in diagnosis of diabetic nephropathy（DN）.Methods Immunoturbidimetry and enzymic method were used to measure casual urine ACR and serum CysC of diabetics patients.Among these patients,29 were confirmed DN and 111 were not confirmed DN.Results The level of casual urine ACR and serum CysC were higher in DN patients than diabetics who were not definited DN（P0.01）.The level of casual urine ACR had a positive correlation with the level of serum CysC in DN patients（P0.01）.Conclusion The ratio of casual urine ACR and serum CysC are useful indicator which can monitor DN.

作者陆琼贾中伟张敏徐元宏

机构地区安徽医科大学第一附属医院检验科

出处《安徽医科大学学报》 CAS 北大核心 2011年第3期273-275,共3页 Acta Universitatis Medicinalis Anhui

关键词白蛋白尿糖尿病肾病肌酸酐 albuminuria creatinine diabetic nephropathies

分类号 R916.4 [医药卫生—药学] R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献3

1LI Hai-xia,XU Guo-bin,WANG Xue-jing,ZHANG Xu-chu,YANG Jian-mei.Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes[J].Chinese Medical Journal,2010(6):745-751. 被引量：15
2董崇周,叶山东,徐将,陈燕,王明丽,赵俐丽,吴凤珍.螺内酯对高糖诱导的大鼠肾小球系膜细胞PAI-1表达的抑制作用[J].安徽医科大学学报,2009,44(6):677-680. 被引量：5
3郭玮,吴炯,唐文佳,朱文欣,潘柏申.不同时段尿白蛋白在诊断早期糖尿病肾脏损伤中的应用[J].中华检验医学杂志,2009,32(10):1091-1095. 被引量：22

二级参考文献40

1Rossing K, Schjoedt K J, Smidt U M, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study [ J ]. Diabetes Care,2005,28 (9) :2106 - 12.
2Sourris K C, Forbes J M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets [ J ]. Curr Drug Targets,2009,10 ( 1 ) :42 - 50.
3Kanwar Y S, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression [J]. Exp Biol Med ( Maywood ) ,2008,233 ( 1 ) :4 - 11.
4Yu X, Li C, Li X, et al. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1 [J]. Toxicol Sci,2007,96 (2) : 346 - 56.
5Eddy A A, Fogo A B. Plasminogen activator inhibitor-1 in chronic kidney disease:evidence and mechanisms of action [J]. J Am Soc Nephrol,2006,17 ( 11 ) :2999 - 3012.
6Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy [J]. Hypertension, 2003,41(1) :64 -8.
7Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats [J]. J Renin Angiotensin Aldosterone Syst ,2007,8 ( 3 ) : 118 - 26.
8Matsumoto S, Takebayashi K, Aso Y. The effect of spironolaetone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy[J]. Metabolism,2006,55 (12) :1645 -52.
9Glorioso N, Filigheddu F, Parpaglia P P, et al. 11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension [J]. Eur Heart J, 2005,26 ( 5 ) : 498 - 504.
10Qian Y, Feldman E, Pennathur S, et al. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy [ J ]. Diabetes,2008,57(6) : 1439 -45.